Get the Stockscreener App
0.95
4.99%
-0.0499
After Hours:
.95
Renovorx Inc Stock (RNXT) Latest News
RenovoRx launches public stock offering - MSN
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders - BioSpace
Can RenovoRx's Premium-Priced Cancer Device Deliver on its $400M Market Potential? - StockTitan
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - BioSpace
RenovoRx Announces $10.9 Million Public Offering of Common Stock - Defense World
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
RenovoRx (RNXT) Lands Major $12.1M Healthcare Investor Backing for Cancer Treatment Launch - StockTitan
A better buy-in window may exist right now for RenovoRx Inc (RNXT) - SETE News
Closing Figures: RenovoRx Inc (RNXT)’s Negative Finish at 1.16, Down -20.55 - The Dwinnex
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
RenovoRx Inc (RNXT) Stock: A Year of Decreases and Increases - The InvestChronicle
RenovoRx Inc (RNXT) Stock: Tracking the Weekly Performance - The News Heater
RenovoRx 11.52M share Spot Secondary priced at $1.05 - MSN
RenovoRx (NASDAQ:RNXT) Stock Price Down 20.5% – Should You Sell? - Defense World
RenovoRx announces proposed public offering - MSN
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Po - GuruFocus.com
RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement - Yahoo Finance
RenovoRx prices public offering to raise $12.1M - MSN
RenovoRx launches public stock offering By Investing.com - Investing.com Nigeria
RenovoRx Announces Pricing Of Public Offering Of About 11.52 Million Shares At $1.05/shr - Nasdaq
RenovoRx Secures Critical $12.1M Funding: Phase III Cancer Study Gets Green Light - StockTitan
Renovorx Announces Pricing Of $12.1 Million Underwritten Public Offering Of Common Stock - Marketscreener.com
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
RenovoRx Raises Fresh Capital to Accelerate Revolutionary Cancer Treatment Platform - StockTitan
Clear Secure Inc (YOU) Shares Plummet Below 1-Year High - The News Heater
Mizuho Financial Group, Inc. ADR’s (MFG) Stock: A Week-by-Week Analysis - The News Heater
RenovoRx: From Clinical Promise To Commercial Reality And Trading At Significant Discount - Seeking Alpha
ASCO GI: RenovoRX’s TAMP system reduces side effects in pancreatic cancer - Yahoo Finance
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 - Business Wire
Analysts Expect Breakeven For RenovoRx, Inc. (NASDAQ:RNXT) Before Long - Yahoo Finance
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - PR Newswire
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Geode Capital Management LLC Grows Stock Holdings in RenovoRx, Inc. (NASDAQ:RNXT) - Defense World
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 - BioSpace
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform - Business Wire
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options - Informazione.it
RenovoRx Expands Phase III Pancreatic Cancer Trial to Major Research Network, Accelerating Patient Enrollment - StockTitan
RNXTRenovorx Inc Latest Stock News & Market Updates - StockTitan
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET - Markets Insider
RenovoRx to Host Fireside Chat on Phase III Cancer Trial Progress and 2025 Strategic Outlook - StockTitan
RenovoRx begins commercialisation of RenovoCath device - Yahoo Finance
RenovoRx begins RenovoCath device sales, eyes market expansion By Investing.com - Investing.com Canada
RenovoRx begins RenovoCath device sales, eyes market expansion - Investing.com India
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System - Markets Insider
Eupraxia Pharmaceuticals Inc (EPRX-Q) QuotePress Release - The Globe and Mail
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial - TipRanks
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):